Navigation Links
Vaccine may double survival in patients with deadly brain tumors
Date:6/2/2008

DURHAM, N.C. -- A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Dukes Preston Robert Tisch Brain Tumor Center.

This vaccine represents a very promising therapy for a cancer that comes out of the blue and robs people of something most of us take for granted -- time, said John Sampson, M.D., Ph.D., a neurosurgeon at Duke and lead investigator on this study. The possibility of doubling expected survival -- with few if any side effects -- would represent a big step and a lot of hope for this group of patients.

Sampson presented the results of this Phase II study during an oral presentation at the annual American Society of Clinical Oncology meeting in Chicago on June 2, 2008. The study was funded by the National Institutes of Health and Celldex Therapeutics, a subsidiary of Avant Immunotherapeutics, which has licensed the rights to the vaccine and provided vaccine for use in the study.

The vaccine targets a protein expressed on about half of all glioblastoma multiforme (GBM) tumors. The protein, known as epithelial growth factor receptor variant III (EGFRvIII), is not expressed in normal tissues but is prevalent in GBMs, which makes it an attractive target for a vaccine, Sampson said.

The vaccine targets the protein and enhances immune response to it, killing tumor cells that express the protein and preventing the re-growth of brain tumors in patients who have already been diagnosed and treated with standard regimens including surgery, chemotherapy and radiation.

This study included 23 patients, treated at Duke and at M.D. Anderson Cancer Center. Patients had all been diagnosed with GBMs, and had been treated with standard therapy. Patients in the trial received vaccine injections monthly and were given a chemotherapeutic agent called temozolomide in conjunction with the vaccine treatments. The temozolomide is thought to enhance the immune response to the EGFRvIII, Sampson said.

This reflected something of a surprising conclusion, because it stands to reason that chemotherapy, which suppresses the bodys immune system, would make the vaccine less effective, Sampson said. What we found was that the opposite is true. While the body is recovering from chemotherapy, immune response is actually stronger as the immune system overcompensates in order to right itself. Its the perfect time to introduce a vaccine.

Patients in the study survived without re-growth of their tumors for a median of 16.6 months, which more than doubles the usual 6.4-month expected progression-free survival in these patients.

Study patients lived for an average of 33.1 months; patients who are diagnosed with GBMs and treated with standard therapy typically live an average of 14.3 months.

Were more than doubling survival time in this group, and we have some patients who are four, five or six years out from diagnosis, which is virtually unheard of in these people, Sampson said.

The vaccine has caused virtually no side effects; swelling at the injection site is often a patients only complaint. A Phase III trial is now open at more than 20 sites nationwide.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... Einstein Medical is proud to announce that ... news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in ... Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations will be held ...
(Date:5/5/2016)... , ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, ... steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction ... be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for Business Journalists , led by the Wharton School’s most prominent professors, ... This one-day program at the Wharton School’s San Francisco campus will feature ...
(Date:5/5/2016)... ... 2016 , ... Derrin Doty Group has unveiled the latest charity campaign in ... west of Seattle. The insurance provider’s caring team has been so moved by the ... to complications from the flu, that they have decided to extend their original campaign. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... master charity program created to assist the people of their local community. The ... nonprofit organizations and community leaders. Their hope is to bring awareness to important ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- Progra m m e ... , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman Islands ... Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, ... Grand Cayman .  MRCU, a global leader in mosquito control, is planning ...
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
Breaking Medicine Technology: